Work

Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.4671.4671

Authors: Kami J. Maddocks, John Pagel, John C. Byrd, Scott Stromatt, Farrukh Awan

Institutions: The Ohio State University, Fred Hutch Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560152574

FWCI: 0.782

Cites:

Cited by: 5

Related to: 10